- Respiratory disease focused Verona Pharma booked a first-half loss, as it ramped up research and development spending.

Pre-tax losses for the six months through June amounted to £17.8m, compared to losses of £16.5m on-year.

R&D costs rose to £15.8m, up from £8.3m on-year.

The company is currently proving up the efficacy of its ensifentrine candidate for the treatment of chronic obstructive pulmonary disease.

At 9:17am: [LON:VRP] Verona Pharma PLC share price was -0.7p at 47.3p

Story provided by